Clinical trials: Non Hodgkin Lymphoma
B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Grade 1 Follicular Lymphoma
Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma
This phase I trial studies the side effects, best way to give, and the best dose of alvocidib when given together with fludarabine phosphate and rituximab in treating patients with previously untreated or relapsed…
- Conditions
- B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Mantle Cell Lymphoma
- Trial name
- NCT00058227
- Testing
- alvocidib, fludarabine phosphate, rituximab
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma
New Combination Regimen of L-asparaginase, Dexamethasone, Ifosfamide, Cisplatin and Etoposide in NK/T-Cell Lymphoma
The purpose of this study is to evaluate the efficacy and tolerability of the combination chemotherapy of L-asparaginase plus DICE regimen in the patients with early stage NK/T-cell lymphoma.
- Trial name
- NCT00933673
- Testing
- L-asp, DXM, IFO, VP-16, DDP
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Fudan University
AML, ALL
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
This is a single-arm study to investigate 1-year treatment related mortality (TRM) in patients with life threatening non-malignant and malignant hematologic disorders who do not have a matched related donor for allogeneic…
- Conditions
- AML, ALL, MDS, MPD Withou Myelofibrosis
- Trial name
- NCT04644016
- Testing
- Clofarabine, Fludarabine, Busulfan
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Diffuse Large B Cell Lymphoma (DLBCL)
Molecular Characterization and Outcomes of Aggressive B-Cell Lymphomas.
This is a retrospective analysis of the presence of chromosomal rearrangements involving MYC, BCL2 and BCL6 genes by FISH in a retrospective, single-center series of large B-cell lymphomas, in order to allow a better…
- Trial name
- CHARTHER (NCT07181785)
- Testing
- Treatments: anthracycline-based combinations followed or not by involved-field radiotherapy
- Where
- Italy
- Volunteers
- 555 people
- Sponsor
- Andrés José Maria Ferreri
Lymphoma, Non-Hodgkin, Lymphoma, B-Cell
Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell
This is a phase 1/1b, interventional single arm, open label, treatment study designed to evaluate the safety and feasibility of infusion of autologous T cells engineered to contain an anti-cluster of differentiation 19 (CD19) and…
- Conditions
- Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Trial name
- NCT03019055
- Testing
- CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg), CAR-20/19-T cells (2.5 x10^5 CAR-20/19-T cells/kg), CAR-20/19-T cells (7.5 x10^5 CAR-20/19-T cells/kg)
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Medical College of Wisconsin
Epstein Barr Virus Associated Non Hodgkin's Lymphoma, Epstein Barr Virus Associated Hodgkin's Lymphoma
Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma
By combining a variety of agents that potentiate Zidovudine (ZDV), the investigators hope to induce remission in this generally fatal disease.
- Conditions
- Epstein Barr Virus Associated Non Hodgkin's Lymphoma, Epstein Barr Virus Associated Hodgkin's Lymphoma, Post-Transplant Lymphoproliferative Disease
- Trial name
- NCT01964755
- Testing
- Doxorubicin, Methotrexate, Leucovorin
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- University of Miami
Non-Hodgkin's Lymphoma
A Study of Peripheral Blood Progenitor Cell (PBPC) Mobilisation by Chemotherapy With Pegfilgrastim or Filgrastim in Subjects With Non-Hodgkin's Lymphoma
The purpose of this study is to evaluate the ability of two different fixed doses of pegfilgrastim (6mg and 12mg) and a by-weight dose of filgrastim (5ug/kg/day) for the mobilisation and collection of PBPCs for autologous…
- Trial name
- NCT00117455
- Testing
- pegfilgrastim, filgrastim
- Sponsor
- Amgen
Leukemia, Lymphoid, Lymphoma, Non-Hodgkin
A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)
A study of the safety, side effects, and effectiveness of LOXO-305 in Chinese adults with lymphoma or chronic leukemia who have already had standard of care treatment. Participation could last up to four years.
- Conditions
- Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell, Lymphoma, Large B-Cell, Diffuse
- Trial name
- NCT04849416
- Testing
- LOXO-305
- Where
- 22 sites in China
- Volunteers
- 87 people
- Sponsor
- Eli Lilly and Company
Mantle Cell Lymphoma
CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma
First-line CAR-T-cell consolidation after an abbreviated induction with 2 cycles of Rituximab and Ibrutinib prior to CAR-T-cell treatment and followed by 6 months of maintenance with Ibrutinib in patients with high risk MCL.
- Trial name
- CARMAN (NCT06482684)
- Testing
- KTE-X19, Ibrutinib
- Where
- 2 sites in Germany
- Volunteers
- 150 people
- Sponsor
- Christian Schmidt, MD
Non-Hodgkin's Lymphoma
A Phase I Dose Escalation Study of RAD001 Administered in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
This study assesses the tolerability, safety, efficacy and pharmacokinetics of everolimus in Japanese patients. Everolimus is administered orally everyday to adult patients with relapsed or refractory non-Hodgkin's lymphoma who…
- Trial name
- NCT00622258
- Testing
- Everolmus
- Where
- 8 sites in Japan
- Volunteers
- 13 people
- Sponsor
- Novartis Pharmaceuticals
Non-Hodgkin's Lymphoma
Phase 1 Study of Radiosensitization Using Bortezomib in Relapsed Non-Hodgkin's Lymphoma Patients Receiving Radioimmunotherapy
This will be a multi-center, Phase I, dose-escalation study of bortezomib in combination with 131I-tositumomab in patients with relapsed non-Hodgkin's lymphoma.
- Trial name
- NCT00777114
- Testing
- bortezomib, tositumomab
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Weill Medical College of Cornell University
Diffuse Large B Cell Lymphoma
Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients With Diffuse Large B-cell Lymphoma (DLBCL)
This is a prospective, single-center, open-label, single-arm clinical study designed to evaluate the efficacy and safety of the Zanubrutinib, Lenalidomide and Rituximab (ZR2) regimen in elderly treatment-naive patient with…
- Trial name
- NCT04460248
- Testing
- Zanubrutinib, Lenalidomide and Rituximab (ZR2)
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Ruijin Hospital
Lymphoma, Large B-Cell, Diffuse, Transplantation
PD-1 Inhibitor Tislelizumab Maintenance Therapy in R/R DLBCL Patients After ASCT
This is a multicenter, randomized controlled, prospective clinical trial. The objective is to investigate the efficacy and safety of Tislelizumab maintenance therapy in newly diagnosed diffuse large B-cell lymphoma (DLBCL)…
- Conditions
- Lymphoma, Large B-Cell, Diffuse, Transplantation, Chemotherapy
- Trial name
- NCT04799314
- Testing
- PD-1 Inhibitor Tislelizumab maintenance therapy
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Ruijin Hospital
Non-Hodgkin's Lymphoma
Safety and Efficacy of KSVCBD Injection in B-cell Non-Hodgkin's Lymphoma Expressing CD19 and/or BCMA
KSVCBD injection is an in vivo Chimeric Antigen Receptor T-Cell (CAR-T cell) therapy product. This multicenter, single-arm, open-label, early exploratory clinical study is designed to evaluate the preliminary safety and efficacy…
- Trial name
- NCT07620314
- Testing
- KSVCBD injection
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Chinese PLA General Hospital
B-cell Lymphoma, Fatigue
Evaluate the Efficacy of Armodafinil for Patients With B-cell Lymphoma and Severe Fatigue
To determine whether armodafinil is more effective than placebo in reducing fatigue.
- Trial name
- NCT01044004
- Testing
- Armodafinil
- Sponsor
- Washington University School of Medicine
Lymphoma, B Cell, Lymphoma Non-Hodgkin
A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies
This study is a Phase 1/2 dose-finding and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV400. The study will enroll patients with relapsed/refractory B-cell malignancies, including large B-cell…
- Conditions
- Lymphoma, B Cell, Lymphoma Non-Hodgkin, High Grade B Cell Lymphoma, Richter Transformation Lymphoma
- Trial name
- NCT07735533
- Testing
- UB-VV400, Rapamycin (sirolimus)
- Where
- United States
- Volunteers
- 274 people
- Sponsor
- Umoja Biopharma
Non-hodgkin's Lymphoma
Clinical Study of SL19+22 CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma
To evaluate the safety and efficacy of SL19+22 in patients with relapsed or refractory non-Hodgkin's lymphoma.
- Trial name
- NCT05206071
- Testing
- CD19+22 CAR-T cells
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
Non-Hodgkin's Lymphoma
Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma (Low-Grade)
Epratuzumab is currently being studied in combination with rituximab, for the treatment of patients with low-grade NHL who failed previous chemotherapy and have never received rituximab or who received rituximab as a single agent…
- Trial name
- NCT00044902
- Testing
- epratuzumab
- Sponsor
- Amgen
Asthma, COPD
Longitudinal Assessment of Clinical Course and BIOmarkers in Severe Chronic AIRway Disease
The aim of the project is to study pathogenetic mechanisms in severe asthma and compare those mechanisms in chronic obstructive pulmonary disease (COPD) in order to test the hypothesis that severe asthma and COPD develop into…
- Trial name
- BIOAIR (NCT00555607)
- Testing
- prednisolone
- Where
- Sweden
- Volunteers
- 233 people
- Sponsor
- Karolinska Institutet
Lymphoma
GM-CSF, Rituximab, and Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Follicular Non-Hodgkin Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00896519
- Testing
- rituximab, sargramostim, cyclophosphamide
- Volunteers
- 30 people
- Sponsor
- French Innovative Leukemia Organisation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.